Laboratory Corporation of America Holdings (NYSE:LH) CEO David P. King sold 132,713 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Laboratory Corporation of America Holdings (LH) opened at 157.55 on Friday. The company’s 50-day moving average price is $156.94 and its 200 day moving average price is $147.10. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The company has a market cap of $16.04 billion, a P/E ratio of 22.07 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.36 earnings per share. On average, equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.52 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/10/insider-selling-laboratory-corporation-of-america-holdings-lh-ceo-sells-20843903-78-in-stock.html.

A number of equities analysts have recently weighed in on the company. Craig Hallum reaffirmed a “buy” rating and set a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Thursday, July 27th. Credit Suisse Group lowered Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a research report on Thursday, July 13th. They noted that the move was a valuation call. Barclays PLC reaffirmed an “overweight” rating and set a $182.00 target price (up from $175.00) on shares of Laboratory Corporation of America Holdings in a research report on Monday, July 17th. BidaskClub raised Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 28th. Finally, ValuEngine raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Laboratory Corporation of America Holdings has an average rating of “Buy” and an average price target of $160.09.

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Laboratory Corporation of America Holdings by 2.3% during the second quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock valued at $1,597,181,000 after buying an additional 231,600 shares during the last quarter. BlackRock Inc. raised its stake in Laboratory Corporation of America Holdings by 3,602.5% during the first quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock valued at $1,158,430,000 after buying an additional 7,856,297 shares during the last quarter. State Street Corp raised its stake in Laboratory Corporation of America Holdings by 2.4% during the first quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock valued at $665,669,000 after buying an additional 109,170 shares during the last quarter. Boston Partners raised its stake in Laboratory Corporation of America Holdings by 4.8% during the second quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock valued at $707,560,000 after buying an additional 210,138 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Laboratory Corporation of America Holdings by 2.0% during the second quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock valued at $415,693,000 after buying an additional 54,100 shares during the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.